8003-22-3
CAS 8003-22-3
8003-22-3 (CAS 8003-22-3) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 12171.846315789473 nM | 72 | - |
| - | EC50 | 36305 nM | 4 | - |
| - | IC50 | 67547 nM | 2 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| YELLOW 11 | 1305581 | SU | MTHSPL |
| D&C YELLOW NO. 11 | 1305581 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 8003-22-3 used for in pharmaceutical contexts?
8003-22-3 (CAS 8003-22-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 8003-22-3?
No adverse-event association or SIDER side-effect rows are rendered for 8003-22-3 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 8003-22-3 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for CI 47000 with EU status "permitted".
What clinical phase is 8003-22-3 in?
No phase 1-4 clinical development badge is rendered for 8003-22-3 because the matched compound identifier rows do not contain a max-phase value.